Funding is the biggest challenge scientists and clinical investigators face when trying to find successful therapies to treat advanced bladder cancer, explained Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine.
Funding is the biggest challenge scientists and clinical investigators face when trying to find successful therapies to treat advanced bladder cancer, explained Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine.
Transcript
What has been the challenge with finding successful therapies to treat advanced bladder cancer?
I think one of the biggest challenges, historically, has always been funding for scientists and clinical investigators to better understand the disease. There has been phenomenal advocacy through groups like the bladder cancer advocacy network to help improve the funding paradigm through their own efforts and through lobbying of the [National Cancer Institute]. It’s certainly nowhere near enough to entice people to come and spend a lot of basic science effort in this field. I think it’s changing. And I think we are going to make great progress.
I think a second aspect, as far as identifying unique therapies and bladder cancer, really has to do with building a link between what we’re understanding more and more of related to genomic alterations and being able to tie that into mechanistically what’s happening at the protein and cell level. Ultimately, as we design drug targets, we’re really looking at the protein and while the genomic signature is so important in helping us understand upstream what’s happening, I think we can’t lose focus on understanding the cell biology that accompanies that.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More